Find a Doctor

Return to Physician Search

Physician Profile

James H Essell MD OHC

James H. Essell, M.D.

Hematologic malignancies, benign hematology, and sarcoma are areas of expertise for Dr. Essell. His sub-specialty is stem cell transplantation. “Many of my family members have had cancer. As a physician, I want to make a difference.”
Learn More.


Blood & Marrow Transplants
Medical Oncology




or call


Hematologic Malignancies (Lymphoma, Myeloma, Leukemia)
Stem Cell Transplantation
Benign Hematology (Coagulopathy, Anemia, Thrombocytopenia)


Hematologic Malignancies
Stem Cell Transplantation
Benign Hematology


Spending time with my family, physical fitness, cycling, running, and weight lifting.


University of Cincinnati


Wilford Hall USAF Medical Center


Wilford Hall USAF Medical Center


Fred Hutchinson Cancer Research Center


American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology


Academy of Medicine, Cincinnati
American Society of Clinical Oncology
American Society of Blood and Marrow Transplantation
American Society of Hematology
Blood and Marrow Transplant Clinical Trials Network
Eastern Cooperative Oncology Group
National Surgical Adjuvant Breast and Bowel Project
Ohio State Medical Society


President Elect, Jewish Hospital Medical Staff
Director, Jewish Hospital Blood & Marrow Transplantation
Jewish Hospital Medical Executive Committee
Jewish Hospital Oncology Committee
Jewish Hospital Infectious Disease Committee
OHC Research Committee

What is a Bone Marrow Transplant? July 10, 2013. Essell, James H.

Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM: Diversity of Organ Site Involvement Among Malignant Lymphomas of Mucosa-Associated Tissues (MALTomas). Am JClin Patho1. 1991: 96: 738-745.

Essell JH, Thompson JM, Harman, GS: Marked Increase in Veno-Occlusive Disease of the Liver Associated with Methotrexate Graft Versus Host Disease Prophylaxis in Patients Receiving Busulfan/Cyclophosphamide. Blood. 1992: 79: 2784-2788.

Essell JH, Thompson JM, Harnlan GS: Pilot Trial of Prophylactic Ursodeoxycholic Acid to Prevent Veno-Occlusive Disease in Allogeneic Bone Marrow Transplant Patients. Bone Marrow Transplant. 1992: 10: 367-372.

Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of Thromboelastography to Bleeding Time and Standard Coagulation Parameters in the Post Cardiopulmonary Bypass Patient. J Cardiothoracic Anesthesia. Aug 1993: 7: 410-415

Snyder MJ, Johnson DB, Dayl MB, Giguere JK, Harman GS, Harden EA, Johnson RA, Leff RS, Mercier RJ, Messerschmidt GL, Rubinsak JR, Essel JH, Halvorson RD, and Thompson JM. Carmustine, Ara-C, Cyclophosphamide and Etoposide with Autologous Bone Marrow Transplantation in Relapsed or Refractory Lymphoma: A Dose-Finding Study. Bone Marrow Transplantation. 1994: 14:595-600.

Kereiakes DJ, Essell JH. Abciximab Associated Profound Thrombocytopenia and Therapy with Immune Globulin and Platelet Transfusion. Am J Cardiology. 1996: 78:1161-1163.

Eisen D, Essell JH, Broun E. Oral Cavity Complications of Bone Marrow Transplantion. Seminars in Cutaneous Medicine and Surgery. 16,1997:265-272.

Eisen D, Essell JH. Drug-Induced Thrombocytopenia Presenting with Isolated Oral Lesions: Report of Two Cases. Cutis 1998 Oct: 62(4):193-5.

Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP , and Thompson JM. Prophylactic Ursodeoxycholic Acid for the Prevention of Hepatic Complications of Allogeneic Bone Marrow Transplantation. A Randomized Controlled Trial. Annals of Internal Medicine 1998 June:15:128(12 Pt 1):975-81.

Eisen D, Essell JH, Broun ER, Sigmund D, Devoe M.  Clinical Utility of Oral Valacyclovir Compared with Oral Acyclovir for the Prevention of Herpes Simplex Virus Mucositis Following Autologous Bone Marrow Transplantation or Stem Cell Rescue Therapy. Bone Marrow Transplant. 2003 Jan: 31(1):51-5.

Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS.  Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: a Southwest Oncology Group Study. Gynecologic Oncology. 2004 Dec: 95(3):506-12.

Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Collander NS, Essell, JH, Flomenberg N, Selby G, Lemaistre CF.  Denileukin Diftitox for the Treatment of Steroid-Resistant Acute Graft-vs-Host Disease. Biology of Blood and Marrow Transplantation. 2005 Mar: 11(3):188-93.

Horwitz ME, Spasojevic I, Morris A, Telen M, Essell JH, Gasparetto C, Sullivan K, Long, G, Chute J, Chao N, Rizzieri D.  Fludarabine-Based Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease with and without Renal Failure: Clinical Outcome and Pharmacokinetics. Biology of Blood and Marrow Transplantation. 2007 Aug:1422-26.

As a member of our OHC physician team, Dr. Essell has full access to the OHC Clinical Trial research program.

We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.

The following are recent reviews provided by actual OHC patients:

"Dr. Essell is my favorite physician. His is the only doctor's office I enjoy going to."

"Dr. Essell is an excellent doctor. He answers my questions with genuine concern, and obviously has a great deal of skill and experience. I believe the communicative treatment I receive certainly helps the mental health aspects of my condition."

"Dr. Essell is the best, caring doctor. We trust him completely."